Executive Team
Holly Meng, MBA
Chief Executive Officer
Holly Meng serves as the Co-founder and Chief Executive Officer of EXIN BioPharma, bringing with her an extensive background of over three decades in business, industry, finance, international trade, higher education, and nonprofit operations. As a seasoned entrepreneur, she has successfully established and exited multiple businesses in her native Hong Kong and her current residence of 25 years in Philadelphia, Pennsylvania. In her capacity as a Senior Specialist of Business with SBA certification at the Fox School, Holly has provided invaluable guidance to more than 50 startups and small-to-medium enterprises (SMEs) in areas such as business planning and operations, funding and investment, marketing, business development, finance, and budgeting. Over the past decade, she has also made significant contributions as the Program Creator and Director of Temple Office of Executive Leadership Education, establishing extensive cross-border networking connections with over a thousand visiting executives, domestic leaders, and organizations on both national and global levels.
Holly has been an active volunteer in numerous nonprofit organizations, holding positions such as President of the American Center for Asian Students, Deputy Curator of the American Chinese Museum, and Vice President of Chinese BioPharmaceutical Association of Greater Philadelphia. In recognition of her exceptional achievements, she was awarded the U.S. President’s Lifetime Achievement Award in 2022. Currently, Holly is pursuing her doctorate in Higher Education Leadership and Policy.
Hanghang Zhang, MD, PhD
Chief Technology Officer
Hanghang Zhang serves as Chief Technology Officer of EXIN BioPharma. He has over 10 years of combined academic and industry experience in drug development spanning epigenetic therapy, cell and gene therapy and artificial intelligence. He was the first scientist in the world that identified CDK9 as a novel epigenetic target and developed a highly potent and selective CDK9 inhibitor, MC180295. A biotech company, EpiGenOnco was founded based on his findings. Hanghang Zhang is also a co-founder of NexStage Bio, which focuses on developing novel technologies and platforms to support cell and gene therapy. Hanghang has been an active volunteer in several nonprofit professional organizations, serving as Executive Council Member of SAPA-GP (Sino-American Pharmaceutical Professionals Association – Greater Philadelphia), and Vice President of CBA-GP (Chinese Biopharmaceutical Association – Greater Philadelphia). He is an active member of SAPA (Sino-American Pharmaceutical Professionals Association), AACR (American Association for Cancer Research), ACACR (Association of Chinese Americans in Cancer Research), APSA (American Physician Scientists Association), CBA (Chinese Biopharmaceutical Association – USA), and CAHON (Chinese American Hematologist and Oncologist Network).
Scientific Advisory Board
Wenhui Hu, MD, PhD
Head of Scientific Advisory Board
Wenhui Hu is the inventor of Exin21 technology and co-founder of EXIN BioPharma. He is a Tenured Professor of Neuroscience and Pathology at Temple University Lewis Katz School of Medicine (TU-LKSM). He has over 35 years of experience in molecular/cellular neuroscience, with specific expertise in gene regulation, signal transduction, and novel biotechnology. He directed the graduate course in Molecular and Cellular Neuroscience for 12 years. His research was funded by the National Institute of Health (10 R01s and 2 R21s) and the Department of Defense in the past 15 years with a total cost of $26 million, focusing on targeted gene therapy (AAV, lentivirus-like particles and nanoparticles), CRISPR/Cas genome editing, HIV/NeuroHIV cure, neurodevelopmental disorders, and gastrointestinal diseases. Dr. Hu has published more than 120 papers in high-impact journals, including PNAS, Mol Therapy, Cell Reports, JEM, JCI, Stem Cells, JBC, etc. He holds six patents. One was exclusively licensed to Excision BioTherapeutics, currently at phase 1/2 clinical trial. His papers have been cited over 6330 times with h-index 38.